Australian regenerative medicine company Orthocell (ASX:OCC) has announced the publication of a successful case study focused on the combination of its CelGro collagen medical device with autologous tenocyte implantation (Ortho-ATI) for the surgical repair of a large degenerate tear of the gluteal medius tendon. …
Orthocell updates on world-first case report for its tendon repair treatment
January 28, 2021 Other HealthAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 31 October
October 31, 2025 - - Podcast -
Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retires
October 31, 2025 - - Australian Biotech -
Immuron provides update on U.S. clinical trials for Travelan and IMM-529
October 31, 2025 - - Australian Biotech -
Firebrick Pharma launches new Nasodine Throat Spray for international markets
October 31, 2025 - - Australian Biotech -
Amplia Therapeutics begins trading on U.S. OTCQB Venture Market
October 31, 2025 - - Australian Biotech -
DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facility
October 31, 2025 - - Latest News -
The continued 'false framing' aims to make us feel guilty for wanting more on health
October 31, 2025 - - Latest News